GlassScriptPhysician profile
Madison Marshall
NPI 1245962570
$1,341.74
in general payments reported to CMS, 2019-2025
27 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $249 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.75 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $190.06 | 2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $166.85 | 2025 | Talvey, Tecvayli, Darzalex |
| Evofem Biosciences, INC. | $134.86 | 2024-2025 | Solosec, Phexx, Phexxi |
| Organon LLC | $134.70 | 2024-2025 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $70.82 | 2025 | |
| Daiichi Sankyo INC. | $59.26 | 2025 | Datroway, Vanflyta |
| Bayer Healthcare Pharmaceuticals INC. | $55.21 | 2025 | |
| Abbvie INC. | $49.35 | 2025 | |
| Pharmaand Gmbh | $42.97 | 2025 | Rubraca |
| Sumitomo Pharma America, INC. | $41.60 | 2024-2025 | Gemtesa, Myfembree |
| Merck Sharp & Dohme LLC | $41.58 | 2025 | Welireg, Keytruda, Reblozyl |
| Genzyme Corporation | $37.21 | 2025 | |
| Deciphera Pharmaceuticals INC. | $29.23 | 2025 | Romvimza, Qinlock |
| Takeda Pharmaceuticals U.S.A., INC. | $27.13 | 2025 | Ninlaro |
| Menarini Silicon Biosystems, INC. | $24.85 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24.19 | 2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $23.26 | 2025 | Opdivo |
| Exeltis, USA INC. | $21.96 | 2025 | Slynd |
| Celgene Corporation | $21.03 | 2025 | Breyanzi |
| Tolmar, INC. | $20.74 | 2025 | Eligard, Rubraca |
| Taiho Oncology, INC. | $19.30 | 2025 | |
| Sage Therapeutics, LLC | $19.17 | 2024 | |
| Emd Serono, INC. | $19.06 | 2025 | |
| Astellas Pharma US INC | $18.94 | 2024 | Veozah |
| Genentech USA, INC. | $17.65 | 2025 | Venclexta |
| Recordati_rare_diseases_inc. | $17.21 | 2025 | Enjaymo |
| Incyte Corporation | $13.55 | 2025 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.